Literature DB >> 8281049

Human T cell leukaemia/lymphoma virus and blood donation.

A G Dalgleish.   

Abstract

Entities:  

Mesh:

Year:  1993        PMID: 8281049      PMCID: PMC1679369          DOI: 10.1136/bmj.307.6914.1224

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  10 in total

1.  Search for human T-cell leukemia virus type I (HTLV-I) proviral sequences by polymerase chain reaction in the central nervous system tissue of HTLV-I-associated myelopathy.

Authors:  Y Ohara; Y Iwasaki; S Izumo; I Kobayashi; A Yoshioka
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis.

Authors:  J K Cruickshank; J H Richardson; O S Morgan; J Porter; P Klenerman; J Knight; A L Newell; P Rudge; A G Dalgleish
Journal:  BMJ       Date:  1990-02-03

3.  Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis.

Authors:  A Ali; S Patterson; K Cruickshank; P Rudge; A G Dalgleish; S C Knight
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

4.  Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells.

Authors:  P Höllsberg; K W Wucherpfennig; L J Ausubel; V Calvo; B E Bierer; D A Hafler
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

5.  Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis.

Authors:  C E Parker; S Daenke; S Nightingale; C R Bangham
Journal:  Virology       Date:  1992-06       Impact factor: 3.616

6.  Prevalence of antibodies to human T cell leukaemia/lymphoma virus in blood donors in north London.

Authors:  M Brennan; J Runganga; J A Barbara; M Contreras; R S Tedder; J A Garson; P W Tuke; P P Mortimer; L McAlpine; J H Tosswill
Journal:  BMJ       Date:  1993-11-13

7.  HTLV-1 infection in tropical spastic paraparesis: lymphocyte culture and serologic response.

Authors:  A Dalgleish; J Richardson; E Matutes; K Cruickshank; A Newell; A Sinclair; R Thorpe; M Brasher; J Weber; D Catovsky
Journal:  AIDS Res Hum Retroviruses       Date:  1988-12       Impact factor: 2.205

8.  In vivo cellular tropism of human T-cell leukemia virus type 1.

Authors:  J H Richardson; A J Edwards; J K Cruickshank; P Rudge; A G Dalgleish
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

9.  High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease.

Authors:  I Elovaara; S Koenig; A Y Brewah; R M Woods; T Lehky; S Jacobson
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

10.  Abnormal in vitro proliferation and differentiation of T cell colony-forming cells in patients with tropical spastic paraparesis/human T lymphocyte virus type I (HTLV-I)-associated myeloencephalopathy and healthy HTLV-I carriers.

Authors:  Y Lunardi-Iskandar; A Gessain; V H Lam; R C Gallo
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

  10 in total
  4 in total

1.  Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis.

Authors:  E Tynell; S Andersson; E Lithander; M Arneborn; J Blomberg; H B Hansson; A Krook; M Nomberg; K Ramstedt; A Shanwell; A Bjorkman
Journal:  BMJ       Date:  1998-05-09

2.  Safe blood? HTLV-1 infection is crippling.

Authors:  J A Copplestone; A G Prentice; M D Hamon; J Gawler; N Anderson
Journal:  BMJ       Date:  1994-01-22

3.  Safe blood? Saving lives costs money.

Authors:  P J Hamilton
Journal:  BMJ       Date:  1994-01-22

Review 4.  Human T-cell lymphotropic-I-associated leukemia/lymphoma.

Authors:  R S Siegel; R B Gartenhaus; T M Kuzel
Journal:  Curr Treat Options Oncol       Date:  2001-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.